Sublingual Versus Vaginal Misoprostol In Medical Treatment of Second Trimestric Missed Miscarriage

Miscarriage Clinical Trial

Official title:

Sublingual Versus Vaginal Misoprostol In Medical Treatment of Second Trimestric Missed Miscarriage: A Randomized Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT05088707
• Other study ID #: aswu/354/3/18
• Status: Not yet recruiting
• Phase: N/A
• Start date: November 1, 2021
• Est. completion date: March 31, 2023

Study information

• Verified date: October 2021
• Source: Aswan University Hospital
• Contact: Hany F Sallam, md
• Phone: +201112505221
• Email: hanysallam876[@]yahoo.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The aim of this work is to compare the effectiveness of vaginal versus sub-lingual misoprostol for medical treatment of the second trimester missed miscarriage

Description:

In women with second trimester-missed miscarriage, sublingual misoprostol may be as vaginal misoprostol in the achievement of successful miscarriage so our aim was to compare the effectiveness of vaginal versus sub-lingual misoprostol for medical treatment of the second trimester missed miscarriage.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: March 31, 2023
• Est. primary completion date: December 31, 2022
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• All women above 18 years of age

• between 13-26 weeks of gestation.

• Pregnancy is confirmed by a pregnancy test or ultrasound scan.

• missed abortion

• Normal general and gynecological examination.

Exclusion Criteria:

• Hemodynamically unstable.

• Suspected sepsis with temperature 38 °C.

• Concurrent medical illness e.g. hematological, cardiovascular, thromboembolism,

• respiratory illnesses, recent liver disease, or pruritus of pregnancy.

• Presence of intrauterine contraceptive device (IUCD).

• Suspect or proven ectopic pregnancy.

• -Failed medical or surgical evacuation before the presentation.

• Known allergy to misoprostol.

Related Conditions & MeSH terms

• Abortion, Missed
• Abortion, Spontaneous
• Miscarriage

Intervention

Drug:
• sublingual misoprostol
All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home. Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose). Paracetamol, eight hourly, will be provided as analgesic or antipyretic. A specimen bottle to collect the POC if passed out. Two pairs of disposable gloves. Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception
• vaginal misoprostol
All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of the second dose will be given upon sending home. Paracetamol, eight hourly, will be provided as analgesic or antipyretic

Locations

Country	Name	City	State
Egypt	Aswan University Hospital	Aswan

Sponsors (1)

Lead Sponsor	Collaborator
Aswan University Hospital

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Completeness of abortion	expulsion of Products of conception by visual inspection	7 days
Secondary	Successful medical abortion	cervical os is closed with endometrial thickness of less than 15 mm	7 days
Secondary	Bleeding pattern following treatment	This will be assessed by hemoglobin(g/dl) and haematocrit level after the treatment , if the patients required blood transfusion and number of units transfused and number of days of bleeding	7 days